William Blair analyst Brandon Vazquez has maintained their bullish stance on PODD stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Insulet’s potential for sustained growth. The company recently held an investor day where it presented updates on its pipeline, commercial strategies, and long-term financial goals. Despite a decline in stock price following the meeting, Vazquez believes that Insulet’s outlined plans for expanding its total addressable market and strengthening its competitive position are promising.
Vazquez is confident that Insulet is on track to achieve its ambitious financial targets, including a projected earnings per share compound annual growth rate of over 25% in the next three years. This growth trajectory justifies the company’s current premium price-to-earnings multiple. Vazquez’s assessment suggests that the market’s initial reaction may not fully reflect the company’s robust growth potential and strategic initiatives.
According to TipRanks, Vazquez is an analyst with an average return of -1.1% and a 48.84% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Ceribell, Inc., Penumbra, and Dexcom.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $360.00 price target.